Investigational Drug Information for XEN1101
✉ Email this page to a colleague
What is the drug development status for XEN1101?
XEN1101 is an investigational drug.
There have been 10 clinical trials for XEN1101.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2022.
The most common disease conditions in clinical trials are Seizures, Disease, and Depressive Disorder, Major. The leading clinical trial sponsors are Xenon Pharmaceuticals Inc., Worldwide Clinical Trials, and National Institute of Mental Health (NIMH).
Summary for XEN1101
| US Patents | 0 |
| International Patents | 37 |
| US Patent Applications | 17 |
| WIPO Patent Applications | 8 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 1 (2022-12-01) |
| Vendors | 20 |
Recent Clinical Trials for XEN1101
| Title | Sponsor | Phase |
|---|---|---|
| An Open-label Study of XEN1101 in Epilepsy | Worldwide Clinical Trials | Phase 3 |
| An Open-label Study of XEN1101 in Epilepsy | Xenon Pharmaceuticals Inc. | Phase 3 |
| A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) | Worldwide Clinical Trials | Phase 3 |
Clinical Trial Summary for XEN1101
Top disease conditions for XEN1101
Top clinical trial sponsors for XEN1101
US Patents for XEN1101
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for XEN1101
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| XEN1101 | Argentina | AR062508 | 2026-08-23 | ⤷ Subscribe |
| XEN1101 | Australia | AU2007288253 | 2026-08-23 | ⤷ Subscribe |
| XEN1101 | Australia | AU2011209731 | 2026-08-23 | ⤷ Subscribe |
| XEN1101 | Brazil | BR112012019199 | 2026-08-23 | ⤷ Subscribe |
| XEN1101 | Brazil | BRPI0716715 | 2026-08-23 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
